These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35203574)

  • 1. Translational Implications of Dysregulated Pathways and microRNA Regulation in Quadruple-Negative Breast Cancer.
    Qattan A; Al-Tweigeri T; Suleman K
    Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quadruple negative breast cancer.
    Huang M; Wu J; Ling R; Li N
    Breast Cancer; 2020 Jul; 27(4):527-533. PubMed ID: 31939077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer molecular subtypes: from TNBC to QNBC.
    Hon JD; Singh B; Sahin A; Du G; Wang J; Wang VY; Deng FM; Zhang DY; Monaco ME; Lee P
    Am J Cancer Res; 2016; 6(9):1864-1872. PubMed ID: 27725895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quadruple Negative Breast Cancers (QNBC) Demonstrate Subtype Consistency among Primary and Recurrent or Metastatic Breast Cancer.
    Angajala A; Mothershed E; Davis MB; Tripathi S; He Q; Bedi D; Dean-Colomb W; Yates C
    Transl Oncol; 2019 Mar; 12(3):493-501. PubMed ID: 30594038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer.
    Kim YJ; Sung M; Oh E; Vrancken MV; Song JY; Jung K; Choi YL
    Cancer Biol Ther; 2018 Apr; 19(4):335-345. PubMed ID: 29333926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial Disparity in Quadruple Negative Breast Cancer: Aggressive Biology and Potential Therapeutic Targeting and Prevention.
    Jinna N; Jovanovic-Talisman T; LaBarge M; Natarajan R; Kittles R; Sistrunk C; Rida P; Seewaldt VL
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response.
    Mohammed AA; Elsayed FM; Algazar M; Rashed HE; Anter AH
    Asian Pac J Cancer Prev; 2020 Feb; 21(2):563-568. PubMed ID: 32102539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential epigenetic modifications implicated in triple- to quadruple-negative breast cancer transition: a review.
    Muhammad A; Forcados GE; Katsayal BS; Bako RS; Aminu S; Sadiq IZ; Abubakar MB; Yusuf AP; Malami I; Faruk M; Ibrahim S; Pase PA; Ahmed S; Abubakar IB; Abubakar M; Yates C
    Epigenomics; 2022 Jun; 14(11):711-726. PubMed ID: 35473304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AR negative triple negative or "quadruple negative" breast cancers in African American women have an enriched basal and immune signature.
    Davis M; Tripathi S; Hughley R; He Q; Bae S; Karanam B; Martini R; Newman L; Colomb W; Grizzle W; Yates C
    PLoS One; 2018; 13(6):e0196909. PubMed ID: 29912871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond Triple-Negative: High Prevalence of Quadruple-Negative Breast Cancer in African Americans.
    Oladeru O; Rajack F; Esnakula A; Naab TJ; Kanaan Y; Ricks-Santi L
    Biomedicines; 2024 Jul; 12(7):. PubMed ID: 39062096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular targets and therapeutic strategies for triple-negative breast cancer.
    Bhat Y; Thrishna MR; Banerjee S
    Mol Biol Rep; 2023 Dec; 50(12):10535-10577. PubMed ID: 37924450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor expression and outcome of neoadjuvant chemotherapy in triple-negative breast cancer.
    Di Leone A; Fragomeni SM; Scardina L; Ionta L; Mulè A; Magno S; Terribile D; Masetti R; Franceschini G
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(4):1910-1915. PubMed ID: 33660830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VNLG-152R and its deuterated analogs potently inhibit/repress triple/quadruple negative breast cancer of diverse racial origins
    Thankan RS; Thomas E; Purushottamachar P; Weber DJ; Ramamurthy VP; Huang W; Kane MA; Njar VCO
    Front Oncol; 2023; 13():1240996. PubMed ID: 37766871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer.
    Wu X; Li Y; Wang J; Wen X; Marcus MT; Daniels G; Zhang DY; Ye F; Wang LH; Du X; Adams S; Singh B; Zavadil J; Lee P; Monaco ME
    PLoS One; 2013; 8(10):e77060. PubMed ID: 24155918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer.
    Riaz N; Idress R; Habib S; Lalani EN
    Front Oncol; 2020; 10():1083. PubMed ID: 32850312
    [No Abstract]   [Full Text] [Related]  

  • 16. Subcellular expression pattern and clinical significance of CBX2 and CBX7 in breast cancer subtypes.
    Park S; Choi J; Song JK; Jang B; Maeng YH
    Med Mol Morphol; 2024 Mar; 57(1):11-22. PubMed ID: 37553450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNAs within the Basal-like signature of Quadruple Negative Breast Cancer impact overall survival in African Americans.
    Angajala A; Raymond H; Muhammad A; Uddin Ahmed MS; Haleema S; Haque M; Wang H; Campbell M; Martini R; Karanam B; Kahn AG; Bedi D; Davis M; Tan M; Dean-Colomb W; Yates C
    Sci Rep; 2022 Dec; 12(1):22178. PubMed ID: 36550153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival.
    Choi YL; Oh E; Park S; Kim Y; Park YH; Song K; Cho EY; Hong YC; Choi JS; Lee JE; Kim JH; Nam SJ; Im YH; Yang JH; Shin YK
    BMC Cancer; 2010 Sep; 10():507. PubMed ID: 20860845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of androgen and microRNA in triple-negative breast cancer.
    Al-Othman N; Ahram M; Alqaraleh M
    Breast Dis; 2020; 39(1):15-27. PubMed ID: 31839601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.